Athanasios C. Tsiatis

2.5k total citations · 1 hit paper
31 papers, 1.4k citations indexed

About

Athanasios C. Tsiatis is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Athanasios C. Tsiatis has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Athanasios C. Tsiatis's work include Prostate Cancer Diagnosis and Treatment (10 papers), Prostate Cancer Treatment and Research (9 papers) and Molecular Biology Techniques and Applications (4 papers). Athanasios C. Tsiatis is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (10 papers), Prostate Cancer Treatment and Research (9 papers) and Molecular Biology Techniques and Applications (4 papers). Athanasios C. Tsiatis collaborates with scholars based in United States, South Korea and Australia. Athanasios C. Tsiatis's co-authors include James R. Eshleman, Kathleen M. Murphy, Michael J. Hafez, Alexis Norris-Kirby, Christopher D. Gocke, Phillip G. Febbo, Tara Maddala, Dejan Knezevic, Matthew R. Cooperberg and Frederick L. Baehner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Athanasios C. Tsiatis

27 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling

2014 447 citations Eric A. Klein, Matthew R. Cooperberg et al. European Urology profile →

Peers

Countries citing papers authored by Athanasios C. Tsiatis

Since Specialization

Citations

This map shows the geographic impact of Athanasios C. Tsiatis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Athanasios C. Tsiatis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Athanasios C. Tsiatis more than expected).

Fields of papers citing papers by Athanasios C. Tsiatis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Athanasios C. Tsiatis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Athanasios C. Tsiatis. The network helps show where Athanasios C. Tsiatis may publish in the future.

Co-authorship network of co-authors of Athanasios C. Tsiatis

This figure shows the co-authorship network connecting the top 25 collaborators of Athanasios C. Tsiatis. A scholar is included among the top collaborators of Athanasios C. Tsiatis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Athanasios C. Tsiatis. Athanasios C. Tsiatis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1323MO ASPEN-03: A randomized phase II study of evorpacept in combination with pembrolizumab in patients with recurrent, unresectable or metastatic (R/M) PD-L1 positive head and neck squamous cell carcinoma (HNSCC) 2025 ·Annals of Oncology ·Bhumsuk Keam, (unknown), J-P. Machiels, Sjoukje F. Oosting, (unknown), (unknown), Alison Forgie, Daniel Brickman, Athanasios C. Tsiatis, Alan B. Sandler, (unknown)	0
2	1324MO ASPEN-04: A randomized phase II study of evorpacept in combination with pembrolizumab and chemotherapy in patients with recurrent, unresectable or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) 2025 ·Annals of Oncology ·(unknown), Ming Hong, Beatriz Cirauqui, J-P. Machiels, Sjoukje F. Oosting, SH Lee, Annette M. Lim, (unknown), Alison Forgie, Daniel Brickman, Athanasios C. Tsiatis, Alan B. Sandler, Bhumsuk Keam	0
3	Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC). 2025 ·Journal of Clinical Oncology ·Kohei Shitara, Zev A. Wainberg, Josep Tabernero, Eric Van Cutsem, Clélia Coutzac, (unknown), Jeeyun Lee, Sun Young Rha, Yoon‐Koo Kang, (unknown), (unknown), Feng Jin, Alison Forgie, Jaume Pons, Athanasios C. Tsiatis, Sophia Randolph, Keun Wook Lee	3
4	Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results. 2024 ·Journal of Clinical Oncology ·Samuel A. Funt, Petros Grivas, Xīn Gào, Daniel A. Vaena, Tian Zhang, Matthew I. Milowsky, (unknown), Harry Liu, Kimberly Tipton, (unknown), Feng Jin, Alison Forgie, Sophia Randolph, Athanasios C. Tsiatis, (unknown)	1
5	Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma. 2021 ·Journal of Clinical Oncology ·Michael S. Gordon, Richard D. Carvajal, Alexander I. Spira, Marilyn Huang, Paul B. Watkins, (unknown), (unknown), (unknown), Bernice Matusow, Chelsea Hope, Jason Halladay, Chao Zhang, (unknown), Athanasios C. Tsiatis, Amita Patnaik	4
6	The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status 2018 ·Urology ·Cristina Magi‐Galluzzi, Sudhir Isharwal, Sara M. Falzarano, Athanasios C. Tsiatis, Anne Dee, Tara Maddala, Dejan Knezevic, Phillip G. Febbo, Jeffrey Lawrence, Eric A. Klein	6
7	A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease 2017 ·European Urology ·Stephen K. Van Den Eeden, Ruixiao Lu, Nan Zhang, Charles P. Quesenberry, Jun Shan, Jeong Han, Athanasios C. Tsiatis, Amethyst Leimpeter, H. Jeffrey Lawrence, Phillip G. Febbo, Joseph C. Presti	89
8	MP20-05 A DIAGNOSTIC BIOPSY-BASED GENOMIC PROSTATE SCORE AS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER DEATH AND METASTASIS IN MEN WITH LOCALIZED PROSTATE CANCER 2017 ·The Journal of Urology ·Stephen Van Den Eeden, Nan Zhang, Jun Shan, Charles P. Quesenberry, Jeong Han, Athanasios C. Tsiatis, Ruixiao Lu, Jeffrey Lawrence, Phillip G. Febbo, Joseph C. Presti	2
9	Clinical validation of a 17-gene genomic prostate score (GPS) assay as a predictor of distant metastases in men with prostate cancer (PCa) treated with radical prostatectomy (RP) in a community setting 2017 ·European Urology Supplements ·(unknown), Nan Zhang, Jun Shan, Charles P. Quesenberry, (unknown), Athanasios C. Tsiatis, Ruixiao Lu, Jeanette A. Lawrence, Phillip G. Febbo, Joseph C. Presti	2
10	P035 Quantitative RT-PCR gene expression in the special histologic subtypes of invasive breast cancer 2015 ·The Breast ·Vivian Tan, (unknown), Carl Yoshizawa, (unknown), Helen D. Bailey, Athanasios C. Tsiatis, (unknown), Steven Shak	1
11	A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer 2014 ·European Urology ·Jennifer Cullen, Inger L. Rosner, Timothy C. Brand, Nan Zhang, Athanasios C. Tsiatis, Joel T. Moncur, Amina Ali, Yongmei Chen, Dejan Knezevic, Tara Maddala, H. Jeffrey Lawrence, Phillip G. Febbo, Shiv Srivastava, Isabell A. Sesterhenn, David G. McLeod	231
12	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling breakdown → 2014 ·European Urology ·Eric A. Klein, Matthew R. Cooperberg, Cristina Magi‐Galluzzi, Jeffry Simko, Sara M. Falzarano, Tara Maddala, June M. Chan, Jianbo Li, Janet E. Cowan, Athanasios C. Tsiatis, Diana B. Cherbavaz, Robert J. Pelham, (unknown), Frederick L. Baehner, Dejan Knezevic, Phillip G. Febbo, Steven Shak, Michael W. Kattan, Mark Lee, Peter R. Carroll	447
13	Validation of a 16-gene signature for prediction of recurrence after nephrectomy in stage I-III clear cell renal cell carcinoma (ccRCC). 2014 ·Journal of Clinical Oncology ·Bernard Escudier, Serge Koscielny, Margarita Lopatin, Christer Svedman, Virginie Verkarre, C. Radulescu, Y. Neuzillet, (unknown), Marc‐Olivier Timsit, Athanasios C. Tsiatis, Michael Bonham, Dejan Knezevic, Thierry Lebrét, Audrey D. Goddard, Arnaud Méjean	4
14	Sarcina Organisms in the Gastrointestinal Tract 2011 ·The American Journal of Surgical Pathology ·Dora Lam‐Himlin, Athanasios C. Tsiatis, Elizabeth A. Montgomery, Rish K. Pai, (unknown), (unknown), Laura W. Lamps, James R. Eshleman, Belur S. Bhagavan, Robert A. Anders	75
15	Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations 2010 ·Journal of Molecular Diagnostics ·Athanasios C. Tsiatis, Alexis Norris-Kirby, (unknown), Michael J. Hafez, Christopher D. Gocke, James R. Eshleman, Kathleen M. Murphy	368
16	Abstract 1781: Use of SNP arrays to assess loss of heterozygosity in gliomas 2010 ·Cancer Research ·Athanasios C. Tsiatis, Michael J. Hafez, Anne Jedlicka, Anirban Maitra, Kathleen M. Murphy, James R. Eshleman	1
17	Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma 2009 ·Modern Pathology ·Athanasios C. Tsiatis, (unknown), Vicki L. Keedy, Jennifer L. Halpern, Ginger E. Holt, Herbert S. Schwartz, Justin Cates	36
18	Cyclooxygenase 2 expression in soft tissue leiomyosarcoma. 2009 ·PubMed ·(unknown), Athanasios C. Tsiatis, Jennifer L. Halpern, Ginger E. Holt, Herbert S. Schwartz, Vicki L. Keedy, Justin Cates	5
19	Primary Hepatic Myxoid Leiomyosarcoma: A Case Report and Review of the Literature 2008 ·Ultrastructural Pathology ·Athanasios C. Tsiatis, James B. Atkinson, J. Kelly Wright, Justin Cates	6
20	Incidence and clinical complications of vancomycin-resistant enterococcus in pediatric stem cell transplant patients 2004 ·Bone Marrow Transplantation ·Athanasios C. Tsiatis, Becky Manes, C Calder, Dean Billheimer, (unknown), Haydar Frangoul	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact